期刊
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
卷 8, 期 1, 页码 51-60出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/153303460900800107
关键词
Cancer; Neuroendocrine tumor; Combined radiopharmaceutical therapy; Linear optimization; Linear program; I-131-MIBG; Y-90-DOTATOC
类别
In this paper, we investigate a previously proposed mathematical model describing the effects that an innovative combined radiopharmaceutical therapy might have on the delivery of radiation to the tumor and limiting critical organs. While focused on a specific dual agent therapy, this investigation will prove mathematically that for any two therapeutic radiopharmaceuticals with different limiting critical organs the model provides patient specific conditions under which combination therapy is superior to single agent therapy. In addition, this paper outlines general methods for calculating the amounts of administered radioactivity for each drug required to optimize tumor radiation dose. We also consider extensions of this model to include an arbitrary number of independent radiopharmaceuticals and/or other treatment factors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据